The GLP Peptide Family Explained

The glucagon-like peptide family belongs to the broader proglucagon-derived peptide group, which arises from tissue-specific post-translational processing of the proglucagon precursor. In enteroendocrine L-cells of the intestine, prohormone convertase 1/3 cleaves proglucagon to yield glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and several related fragments. This article summarizes the family at a laboratory-research level and does not describe therapeutic use.

GLP-1 is the most extensively studied member of the family. Its receptor, GLP-1R, is a class B G-protein-coupled receptor expressed in pancreatic islets, the central nervous system, and other tissues. In cellular assays it couples primarily to Gαs and elevates intracellular cAMP, a signaling readout that has been characterized in HEK293 and CHO cell lines stably expressing recombinant GLP-1R. Reviews on PubMed cover the receptor pharmacology in depth.

The ENOS compound pages for the materials discussed here, each with its own lot certificate of analysis, are Retatrutide 10MG, Retatrutide 20MG, Retatrutide 30MG, Retatrutide 60MG and Tirzepatide 10MG.

GLP-2 shares sequence homology with GLP-1 but signals through a distinct receptor, GLP-2R, with a tissue distribution centered on the gastrointestinal tract. Research literature has focused on its role in intestinal epithelial biology in preclinical models. The two peptides are typically studied with different in-vitro assay platforms even though their precursor and processing pathway overlap.

The tri-agonist class refers to synthetic peptide analogs engineered to activate more than one receptor within the incretin and glucagon family — commonly some combination of GLP-1R, glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). These molecules are of active research interest in receptor pharmacology and structure–activity relationship studies. In-vitro characterization typically involves parallel cAMP or β-arrestin recruitment assays across each recombinant receptor to quantify relative potency.

For any of these peptides, laboratory work depends on well-characterized reference material. Sequence variants, single amino-acid substitutions, and fatty-acid conjugates behave differently in receptor-binding assays, so the identity documentation on the COA — full sequence, molecular weight, and purity — is not a formality but a prerequisite for interpretable results. Storage and reconstitution follow the general principles outlined elsewhere in these lab notes.

All materials described are for in-vitro laboratory research only and are not for human or veterinary use.